July 2013 Editor's Picks: Products from Honeywell and PTI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

July 2013 Editor's Picks: Products from Honeywell and PTI

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Honeywell
Software helps operators better manage manufacturing systems.

Software from Honeywell is designed to improve operational excellence by helping plant workers redefine how they maintain system uptime and reliability while providing safer operations. The Intuition Operations Monitoring software, built on Honeywell’s Intuition platform, is used to help operators keep the process within the best operating zone.  The Control Performance Monitoring software helps engineers to monitor, identify, diagnose, and remedy process-control asset issues across all plant layers.  Honeywell’s latest Alarm Management software helps operators better manage their processes without compromising safe operations.


Pharma Technology Inc.
Tablet deduster line offers high-containment with wash-in-place or wash-offline models.

Pharma Technology Inc. (PTI) added high-containment, dust-tight models; wash-in-place (WIP) models; and wash-offline (WOL) models to its PharmFlex line of dedusters. The new models can be used in PTI’s All-In-One (AIO) Tablet Deduster and Tester System. The high-containment, dust-tight model features pinch valves on the tablet inlet, air inlet, and dust extraction ports, as well as PTI’s FlexConnect dust-tight connection, which utilizes FDA-accepted silicone rimming that mates with circular ribs on the inlet and outlet ports. The model includes a pressure-decay test system integrated into the startup routine to ensure full containment and continuous negative-pressure monitoring during operation. The high-containment model is also available as a WIP or WOL model.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Equipment and Processing Report,
Click here